The pharmaceuticals sector continues to face headwinds due to 1) fierce competition, 2) shorter time-to-market, 3) expiring patents, 4) slowing sales growth, 5) declining profitability in developed markets and above all 6) continually receiving 483s at their plants from USFDA. Thus they need to find solutions to beat these challenges. Additional woes adding on the domestic front are the regulatory issues which are negatively impacting the near-term outlook. We maintain a cautious view on the sector and recommend being stock specific as 1) plant approvals from the US FDA and 2)key product launches in US continue to directly impact the earnings....